Close menu

Contact

New generation of biotherapy monitoring by mass spectrometry

Recognized expertise in mass spectrometry-based quantification methods
Unique know-how for the production of Stable Isotope Labelled proteins

About our company 

Promise Proteomics was created in 2010 as a spin-off of CEA Grenoble. This medtech is currently wholly owned by the Aguettant group and is directed by Dr Eric Rougemond.

Its business model is based on a range of services in bioproduction and on the development of products to label and quantify proteins in biological samples.
Since 2013, Promise has been a partner in an innovative and ambitious R&D programme which has allowed it to develop its technology, on which the diagnostic kits for personalised medical applications are based.

Capitalising on its unique know-how in the production of internal standards for protein assays and its recognised expertise in mass spectrometry-based quantification methods,

Promise Proteomics is placing its skills at the service of health care professionals through its mAb-X-mise kits

 

Promise Proteomics

Experience and Innovation
for targeted protein quantification

Promise Proteomics provides  stable isotope labelled proteins (SIL proteins)  for the quantification of proteins in biological samples.

Contact

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.